查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010014

分子診斷市場：2026-2032年全球市場預測（按產品、技術、檢體類型、檢測類型、應用和最終用戶分類）

Molecular Diagnostics Market by Offering, Technology, Specimen Type, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，分子診斷市場價值將達到 318.6 億美元，到 2026 年將成長至 362.6 億美元，到 2032 年將達到 816 億美元，複合年成長率為 14.38%。

主要市場統計數據
基準年 2025 318.6億美元
預計年份：2026年 362.6億美元
預測年份 2032 816億美元
複合年成長率 (%) 14.38%

探索分子診斷市場的基礎、技術創新、臨床促進因素和新興機會。

分子診斷已成為現代醫療保健服務的基石，它以前所未有的精準度在基因和分子層面上檢測、表徵和監測疾病。該領域涵蓋了廣泛的檢測方法和分析平台，旨在識別特定的基因突變、病原體和生物標記物，從而實現個人化治療策略並改善患者預後。檢測靈敏度的提高，以及定序和先進影像技術成本的降低，正在加速分子診斷工具在臨床檢查室、研究機構和照護現場的應用。

從與個人化醫療的融合到監管演變以及臨床檢測技術的融合，揭示正在重新定義分子診斷的顛覆性變革。

分子診斷領域正經歷著翻天覆地的變革，這主要得益於檢測技術、數據分析以及與治療手段整合的進步。隨著基因組分析和基於生物標記的療法在腫瘤學和罕見疾病管理中變得至關重要，個人化醫療已從理論上的可能性變為現實。數位病理學和人工智慧平台進一步加速了這項變革，它們簡化了影像解讀和預測建模流程，從而提高了診斷的準確性。

到 2025 年，對美國新的關稅政策對分子診斷供應鏈成本和策略製造重組的影響進行全面評估。

預計到2025年，美國關稅政策的變化可能會對分子診斷產業的成本結構和供應鏈策略產生重大影響。隨著進口試劑、儀器和配件關稅的提案上調，製造商和實驗室正準備應對可能轉嫁給醫療服務提供者和患者的投入成本增加。這種情況凸顯了策略採購和供應鏈多元化對於減輕關稅對價格壓力的影響的重要性。

對所提供的技術、檢體類型、測試形式、應用領域和最終用戶概況進行詳細分析，以推動分子診斷領域的策略性細分。

對市場的詳細分析表明，每個產品細分市場都提供獨特的價值提案。儀器提供硬體基礎，試劑和試劑盒提供生化特異性，軟體和服務則實現資料管理和解讀分析。整體情況包括用於染色體和基因定位的螢光雜合反應、用於蛋白質組學分析的質譜技術、用於平行靶向篩檢的微陣列檢測技術、用於EXOME、RNA、靶向和全基因組測序的次世代定序，以及聚合酵素鏈鎖反應(PCR) 平台，包括數字、多重和即時等多種形式。

本報告將闡明美洲、歐洲、中東和非洲以及亞太地區分子診斷醫療基礎設施的採用、市場成熟度、投資趨勢和區域差異。

美洲、歐洲、中東和非洲（EMEA）以及亞太地區的區域市場動態受到經濟、監管和醫療基礎設施等多種因素的影響。在美洲，完善的醫保體系和主要企業的集中佈局推動了先進診斷方法的快速普及，而官民合作關係則加速了液態生物檢體和伴隨診斷等領域的創新。北美在監管清晰度方面仍處於領先地位，監管機構引領適應性核准流程，並鼓勵整合真實世界數據。

對領先的分子診斷公司進行概況分析，重點在於塑造市場領導趨勢趨勢的競​​爭策略、創新、夥伴關係和研發投資。

分子診斷領域的主要企業正透過對次世代定序能力的定向投資、試劑供應的策略合作以及人工智慧解讀工具的整合來凸顯自身優勢。一些公司已建立專門的卓越中心，以加速檢測方法的開發並簡化臨床檢驗；而另一些公司則透過併購來拓展產品系列併進入新興市場。與製藥公司的合作正在擴大伴隨診斷在臨床試驗設計和治療策略制定中的作用。

為產業領導者提供切實可行的策略建議，以降低風險、簡化市場進入流程並抓住分子診斷領域的新機會。

為了在不斷發展的分子診斷領域取得成功，產業領導者應優先考慮多元化其策略組合，進軍液態生物檢體和數位PCR等高成長技術領域。開發能夠同時支援集中式檢查室工作流程和照護現場（PoC）應用的模組化平台，將有助於擴大市場覆蓋範圍並保障業務永續營運。同時，與試劑供應商和學術機構建立夥伴關係，將有助於降低供應鏈風險並加快檢測方法的檢驗。

一套全面的調查方法，詳細介紹了資料收集、一手和二手資訊、檢驗過程以及支持對分子診斷進行深入分析的分析框架。

本研究採用嚴謹的多階段調查方法，確保獲得全面且準確的見解。主要數據透過對關鍵相關人員（包括檢查室管理人員、臨床研究人員和監管專家）的深入訪談收集。除這些定性研究外，還對醫院和獨立實驗室的決策者進行了結構化問卷調查，以獲取他們對技術應用、營運挑戰和發展重點的第一手觀點。

本報告整合了關鍵見解和策略挑戰，最後深入分析了分子診斷市場的趨勢、創新、挑戰以及實現永續成長和韌性的途徑。

總而言之，在技術創新、不斷變化的監管環境和不斷擴展的臨床應用的推動下，分子診斷市場正處於變革性成長的轉折點。從產品、技術、檢體類型、檢測形式、應用和最終用戶等方面進行策略性細分，揭示一個複雜的生態系統，其中有針對性的投資和合作夥伴關係對於持續成功至關重要。區域趨勢進一步凸顯了針對不同的醫療基礎設施和政策環境採取客製化方法的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 分子診斷市場：依產品/服務分類

  • 裝置
  • 試劑和試劑盒
  • 軟體服務

第9章 分子診斷市場：依技術分類

  • 基於螢光的雜合反應
  • 質譜分析
  • 微陣列分析
  • 次世代定序
    • EXOME定序
    • RNA定序
    • 目標序列
    • 全基因組定序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 多重PCR
    • 即時PCR

第10章 依檢體類型分類的分子診斷市場

  • 血
  • 腦脊髓液（CSF）
  • 鼻咽拭子
  • 唾液
  • 航班
  • 組織切片檢查
  • 尿

第11章 依檢測類型分類的分子診斷市場

  • 檢查室基地
    • 中心檢查室
    • 醫院檢查室
    • 獨立測試機構
  • 照護端

第12章 分子診斷市場：依應用分類

  • 基因檢測
    • 基因帶原檢測
    • 診斷測試
    • 預測性測試
  • 感染疾病
    • 細菌
    • 寄生蟲
    • 病毒
  • 腫瘤學
    • 液態生物檢體
    • 微量殘存疾病
    • 組織切片檢查
  • 產前檢查
    • 侵入性
    • 非侵入性

第13章 分子診斷市場：依最終用戶分類

  • 學術和研究機構
  • 診斷檢查室
  • 醫院和診所

第14章 分子診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 分子診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 分子診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國分子診斷市場

第18章：中國分子診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories Inc.
  • ADT Biotech Co., Ltd.
  • AstraZeneca plc
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMerieux SA
  • Castle Biosciences, Inc.
  • Danaher Corporation
  • Diasorin Sp,A.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Oxford Nanopore Technologies
  • QIAGEN NV
  • Siemens Healthineers AG
  • Source BioScience
  • Sysmex Corporation by Oxford Gene Technology
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D46

The Molecular Diagnostics Market was valued at USD 31.86 billion in 2025 and is projected to grow to USD 36.26 billion in 2026, with a CAGR of 14.38%, reaching USD 81.60 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 31.86 billion
Estimated Year [2026] USD 36.26 billion
Forecast Year [2032] USD 81.60 billion
CAGR (%) 14.38%

Exploring the Molecular Diagnostics Market's Foundations Technological Innovations Clinical Drivers and Emerging Opportunities in Healthcare Delivery

Molecular diagnostics has emerged as a cornerstone of modern healthcare delivery by offering unprecedented precision in detecting, characterizing, and monitoring disease at the genetic and molecular levels. This field encompasses a broad array of assays and analytical platforms designed to identify specific genetic mutations, pathogens, and biomarkers, thereby enabling personalized treatment strategies and improving patient outcomes. Progress in assay sensitivity, coupled with the declining cost of sequencing and advanced imaging, has fueled widespread adoption of molecular diagnostic tools across clinical laboratories, research institutions, and point-of-care settings.

Technological breakthroughs in next-generation sequencing, polymerase chain reaction enhancements, and mass spectrometry have catalyzed the expansion of testing capabilities, while regulatory frameworks have adapted to accelerate approvals for innovative diagnostics. Concurrent investments in laboratory infrastructure and digital integration are reinforcing the interoperability of data systems, facilitating seamless flow of patient information and rapid clinical decision-making. Moreover, the convergence of diagnostics and therapeutics, often referred to as theranostics, positions molecular assays at the heart of targeted treatment protocols.

Looking ahead, the interplay of evolving regulatory landscapes, reimbursement strategies, and shifting clinical needs will determine the trajectory of market growth. Stakeholders must navigate complex operational challenges, including scalability, quality control, and supply chain resilience, while capitalizing on opportunities presented by emerging applications in oncology, infectious diseases, and genetic screening. The collective momentum behind molecular diagnostics underscores its critical role in reshaping patient care paradigms and driving the next frontier of precision medicine.

Unveiling the Disruptive Shifts Redefining Molecular Diagnostics from Personalized Medicine Integration to Regulatory Evolution and Technological Convergence in Clinical Testing

The molecular diagnostics landscape is undergoing a seismic transformation driven by advancements in assay technologies, data analytics, and therapeutic integration. Personalized medicine has shifted from theoretical promise to tangible reality as genomic profiling and biomarker-guided therapies become integral to oncology and rare disease management. This evolution is further amplified by digital pathology and artificial intelligence platforms that streamline image interpretation and predictive modeling, enhancing diagnostic precision.

Regulatory authorities are responding to these shifts with adaptive pathways designed to expedite market entry for high-impact assays, though this progress is accompanied by heightened scrutiny on clinical validation and post-market surveillance. At the same time, cost-containment pressures and demands for real-world evidence are compelling manufacturers to demonstrate value through outcome-based studies. The COVID-19 pandemic served as a catalyst, proving the agility of molecular diagnostic developers in scaling production of high-throughput tests and fostering public-private collaborations to address emergent health crises.

As a result, stakeholders are witnessing a convergence of decentralization trends and centralized laboratory capabilities. Point-of-care platforms have matured, offering rapid turnaround times and ease of use, while centralized labs continue to push the boundaries of multiplexed assays and ultra-high-throughput sequencing. This duality enables a more robust diagnostic ecosystem capable of responding to both routine screening needs and large-scale surveillance demands. Consequently, market players are reevaluating their portfolios and forging strategic alliances to align with these disruptive currents, ensuring resilience and relevance in a rapidly evolving environment.

Assessing the Comprehensive Effects of New United States Tariff Policies on Molecular Diagnostics Supply Chains Costs and Strategic Manufacturing Realignments by 2025

Anticipated changes to United States tariff policies by 2025 are poised to exert a profound influence on the molecular diagnostics industry's cost structures and supply chain strategies. With proposals to levy higher duties on imported reagents, instrumentation and ancillary components, manufacturers and laboratories brace for increased input costs that could be passed downstream to healthcare providers and patients. This scenario underscores the need for strategic sourcing and supply base diversification to mitigate exposure to tariff-induced price pressures.

In response, some instrument producers are examining options to localize assembly operations or to establish captive reagent manufacturing facilities within domestic borders. Such initiatives may alleviate tariff burdens but could entail significant capital investment and extended timelines to achieve regulatory compliance. Simultaneously, diagnostic developers are engaging in proactive negotiations with distributors to secure long-term supply contracts, adopting dual sourcing agreements and exploring nearshoring opportunities for critical materials.

The cumulative effect of these measures will reshape competitive dynamics as companies with robust vertical integration and supply chain agility gain a cost advantage. Meanwhile, smaller firms may struggle to absorb elevated duties without compromising profitability or passing costs to end users. Policy uncertainty further complicates investment decisions, compelling stakeholders to model various tariff scenarios and to establish contingency frameworks. In this climate, collaboration across the value chain-from raw material suppliers to end-user laboratories-will be essential to preserve access to cutting-edge molecular diagnostic solutions and to maintain continuity of patient care.

Deep Dive into Offerings Technologies Specimen Types Test Formats Application Areas and End User Profiles Driving Strategic Segmentation in Molecular Diagnostics

A nuanced exploration of the market reveals that each offering segment contributes unique value propositions, with instruments providing the hardware backbone, reagents and kits delivering the biochemical specificity, and software and services enabling data management and interpretive analytics. The technology landscape spans fluorescence in situ hybridization for chromosomal and gene mapping, mass spectrometry for proteomic analysis, microarray assays for parallel target screening, next-generation sequencing in its exome, RNA, targeted and whole-genome modalities, and polymerase chain reaction platforms encompassing digital, multiplex and real-time variants.

Specimen type diversity reflects the versatility of molecular assays, from blood and cerebrospinal fluid to nasal and throat swabs, saliva, stool, tissue biopsies and urine, each presenting distinct preprocessing and analytical requirements. Test type categorization underscores the coexistence of laboratory-based models-with central, hospital and independent lab infrastructures-and point-of-care systems optimized for rapid, decentralized diagnostics. Application areas span genetic testing through carrier, diagnostic and predictive services; infectious disease detection of bacterial, parasitic and viral pathogens; oncology monitoring via liquid biopsy, minimal residual disease assessment and tissue biopsy; and prenatal testing in invasive and noninvasive formats.

End users range from academic and research institutes pioneering assay development, to diagnostic laboratories specializing in high-throughput testing, and hospitals and clinics delivering frontline patient services. These segments exhibit varying capital intensity, regulatory demands and adoption curves. By understanding the interplay among offerings, technologies, specimen types, test formats, application areas and end-user profiles, stakeholders can tailor strategic initiatives and product portfolios to address evolving clinical needs and market dynamics.

Illuminating Regional Variations in Molecular Diagnostics Adoption Market Maturation Investment Trends and Healthcare Infrastructure Across Americas EMEA and Asia Pacific

Regional market dynamics are shaped by diverse economic, regulatory and healthcare infrastructure factors across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, a well-established reimbursement environment and concentration of leading diagnostic companies foster rapid adoption of advanced assays, while public-private partnerships accelerate innovation in areas such as liquid biopsy and companion diagnostics. North America remains a bellwether for regulatory clarity, with agencies pioneering adaptive approval pathways and encouraging real-world data integration.

Europe, the Middle East and Africa collectively present a mosaic of maturity levels. Western Europe benefits from harmonized regulatory frameworks and robust funding for precision medicine initiatives, whereas the Middle East is witnessing strategic investments in healthcare infrastructure and molecular testing capabilities. In select African markets, growth is driven by infectious disease surveillance programs, yet challenges persist around laboratory capacity and supply chain reliability. Cross-border collaborations and capacity-building efforts are helping to bridge gaps and to expand testing accessibility in underserved regions.

The Asia-Pacific region is characterized by rapid expansion of domestic diagnostics players and government-led initiatives to bolster genomic medicine. Countries such as China, India and Japan are scaling up sequencing centers and point-of-care testing networks to support large-scale screening and public health monitoring. Regulatory authorities in these markets are increasingly aligning with international standards, facilitating expedited approvals for high-impact assays. Collectively, this regional diversity underscores the importance of tailored entry strategies and localized partnerships to capitalize on varying growth trajectories and healthcare priorities.

Profiling Leading Molecular Diagnostics Companies Highlighting Competitive Strategies Innovations Partnerships and R&D Investments Shaping Market Leadership Dynamics

Leading companies in molecular diagnostics are distinguishing themselves through targeted investments in next-generation sequencing capabilities, strategic alliances for reagent supply and the integration of AI-driven interpretive tools. Some have established dedicated centers of excellence to accelerate assay development and to streamline clinical validation, while others pursue mergers and acquisitions to broaden their product portfolios and to gain access to emerging markets. Collaborative ventures with pharmaceutical firms are amplifying the role of companion diagnostics in clinical trial design and therapeutic decision-making.

Innovation is also thriving among mid-sized organizations that specialize in niche applications such as digital PCR or rapid point-of-care platforms. These players focus on agility, leveraging modular instrument architectures and cloud-based analytic pipelines to reduce deployment time and to enable remote monitoring. Furthermore, partnerships between diagnostic developers and academic research institutes are producing cutting-edge assays for rare diseases and novel oncology biomarkers, often underpinned by co-development agreements that share both technical expertise and commercialization risk.

As a result, the competitive landscape is evolving toward an ecosystem model in which product vendors, software providers and service laboratories form interconnected networks. This approach enhances end-to-end solutions for customers, offering seamless workflows from sample collection to data reporting. Companies that can demonstrate comprehensive offerings, strong regulatory track records and scalable manufacturing capabilities are best positioned to secure long-term contracts with healthcare systems and to maintain a leading edge in this dynamic market.

Actionable Strategic Recommendations for Industry Leaders to Capitalize on Emerging Molecular Diagnostics Opportunities While Mitigating Risks and Streamlining Market Entry

To thrive in the shifting molecular diagnostics environment, industry leaders should prioritize strategic portfolio diversification by expanding into high-growth technology areas such as liquid biopsy and digital PCR. Developing modular platforms that accommodate both centralized laboratory workflows and point-of-care applications will enhance market reach and resilience. Concurrently, forging partnerships with reagent suppliers and academic institutions can mitigate supply chain risks and accelerate assay validation.

Leaders must also deepen engagement with payers and regulatory bodies to establish value-based reimbursement frameworks that reward diagnostic-driven treatment pathways. Investing in real-world evidence generation through longitudinal studies and patient registries will strengthen economic value propositions. On the operational front, optimizing manufacturing footprints via nearshoring or dual sourcing arrangements can offset potential tariff impacts and ensure continuity of critical supplies.

Moreover, integrating artificial intelligence and machine learning into data analysis pipelines will differentiate offerings by delivering actionable insights and predictive capabilities. Embracing digital connectivity to support remote diagnostics and telehealth services will address evolving provider and patient needs. Finally, fostering a culture of continuous learning and cross-functional collaboration within organizations will expedite innovation and enable rapid adaptation to emerging market trends and regulatory changes.

Comprehensive Research Methodology Detailing Data Collection Primary and Secondary Sources Validation Processes and Analytical Frameworks Underpinning Molecular Diagnostics Insights

This research initiative employed a rigorous multi-phase methodology to ensure comprehensive and accurate insights. Primary data was gathered through in-depth interviews with key stakeholders, including laboratory directors, clinical researchers and regulatory experts. These qualitative engagements were complemented by structured surveys targeting decision-makers across hospital and independent laboratory settings, capturing firsthand perspectives on technology adoption, operational challenges and growth priorities.

Secondary research entailed systematic review of peer-reviewed scientific literature, regulatory filings and industry reports to contextualize primary findings within broader market and policy trends. Company press releases, patent filings and financial disclosures provided additional granularity on competitive strategies and innovation trajectories. Data points were triangulated through cross-validation techniques to identify and reconcile discrepancies, ensuring robustness and credibility.

Analytical frameworks incorporated both qualitative thematic analysis and quantitative trend modeling. Segmentation analyses were refined through iterative feedback loops with domain experts, aligning market categorizations with real-world clinical workflows. All findings underwent rigorous peer review and quality assurance checks, verifying the integrity of data inputs and the validity of interpretive conclusions. This methodological rigor underpins the reliability of strategic recommendations and the actionable intelligence presented throughout the report.

Synthesizing Key Insights and Strategic Imperatives to Conclude Molecular Diagnostics Market Trends Innovations Challenges and Pathways for Sustainable Growth and Resilience

In summary, the molecular diagnostics market stands at the cusp of transformative growth, propelled by technological innovations, regulatory evolutions and expanding clinical applications. Strategic segmentation across offerings, technologies, specimen types test formats applications and end users reveals a complex ecosystem where targeted investments and collaborative partnerships are essential to sustainable success. Regional dynamics further underscore the necessity of customized approaches to navigate diverse healthcare infrastructures and policy landscapes.

Competitive positioning will hinge on an organization's ability to integrate advanced analytics, maintain supply chain resilience and demonstrate tangible value through robust clinical and economic evidence. Companies that prioritize agility-balancing centralized laboratory capabilities with decentralized point-of-care solutions-will be well-equipped to address both routine diagnostic demands and emergent public health challenges. Moreover, proactive engagement with regulators and payers will facilitate streamlined approvals and favorable reimbursement pathways.

Ultimately, the path forward requires a harmonious blend of innovation, collaboration and strategic foresight. By leveraging actionable insights into market trends, stakeholders can anticipate shifts, mitigate risks and capitalize on emerging opportunities, thereby driving the next wave of precision medicine advancements and delivering improved patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Diagnostics Market, by Offering

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Molecular Diagnostics Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Mass Spectrometry
  • 9.3. Microarray Analysis
  • 9.4. Next-Generation Sequencing
    • 9.4.1. Exome Sequencing
    • 9.4.2. RNA Sequencing
    • 9.4.3. Targeted Sequencing
    • 9.4.4. Whole Genome Sequencing
  • 9.5. Polymerase Chain Reaction
    • 9.5.1. Digital PCR
    • 9.5.2. Multiplex PCR
    • 9.5.3. Real-Time PCR

10. Molecular Diagnostics Market, by Specimen Type

  • 10.1. Blood
  • 10.2. Cerebrospinal Fluid (CSF)
  • 10.3. Nasal/Throat Swabs
  • 10.4. Saliva
  • 10.5. Stool
  • 10.6. Tissue Biopsies
  • 10.7. Urine

11. Molecular Diagnostics Market, by Test Type

  • 11.1. Laboratory Based
    • 11.1.1. Central Lab
    • 11.1.2. Hospital Lab
    • 11.1.3. Independent Lab
  • 11.2. Point Of Care

12. Molecular Diagnostics Market, by Application

  • 12.1. Genetic Testing
    • 12.1.1. Carrier Testing
    • 12.1.2. Diagnostic Testing
    • 12.1.3. Predictive Testing
  • 12.2. Infectious Disease
    • 12.2.1. Bacterial
    • 12.2.2. Parasitic
    • 12.2.3. Viral
  • 12.3. Oncology
    • 12.3.1. Liquid Biopsy
    • 12.3.2. Minimal Residual Disease
    • 12.3.3. Tissue Biopsy
  • 12.4. Prenatal Testing
    • 12.4.1. Invasive
    • 12.4.2. Non-Invasive

13. Molecular Diagnostics Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals & Clinics

14. Molecular Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Molecular Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Molecular Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Molecular Diagnostics Market

18. China Molecular Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories Inc.
  • 19.6. ADT Biotech Co., Ltd.
  • 19.7. AstraZeneca plc
  • 19.8. Becton, Dickinson, and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Biocartis Group NV
  • 19.11. bioMerieux SA
  • 19.12. Castle Biosciences, Inc.
  • 19.13. Danaher Corporation
  • 19.14. Diasorin S.p,A.
  • 19.15. Exact Sciences Corporation
  • 19.16. F. Hoffmann-La Roche AG
  • 19.17. Grifols S.A.
  • 19.18. Guardant Health, Inc.
  • 19.19. Hologic, Inc.
  • 19.20. Illumina, Inc.
  • 19.21. Laboratory Corporation of America Holdings
  • 19.22. Myriad Genetics, Inc.
  • 19.23. Oxford Nanopore Technologies
  • 19.24. QIAGEN N.V.
  • 19.25. Siemens Healthineers AG
  • 19.26. Source BioScience
  • 19.27. Sysmex Corporation by Oxford Gene Technology
  • 19.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASAL/THROAT SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NON-INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 280. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 282. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 283. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 286. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 288. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 289. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 291. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS MOLECULAR DIAGNOSTI